Laura J. Esserman focuses on Breast cancer, Cancer, Internal medicine, Oncology and Neoadjuvant therapy. Her Breast cancer research includes themes of Magnetic resonance imaging, Surgery, Chemotherapy and Pathology. Her biological study spans a wide range of topics, including Mastectomy and Cohort.
The concepts of her Cancer study are interwoven with issues in Clinical trial, Disease, Lymph node and Carcinoma. As part of one scientific family, Laura J. Esserman deals mainly with the area of Internal medicine, narrowing it down to issues related to the Gynecology, and often Taxane, Anthracycline and Gastroenterology. Her Oncology study incorporates themes from Aromatase inhibitor, Prostate, Incidence, Proportional hazards model and Prostate cancer.
Her scientific interests lie mostly in Breast cancer, Internal medicine, Oncology, Cancer and Surgery. Her Breast cancer research integrates issues from Clinical trial, Radiology and Chemotherapy. Her studies link Gynecology with Internal medicine.
Her Oncology study integrates concerns from other disciplines, such as Proportional hazards model, MammaPrint, Disease and Trastuzumab. Her Cancer research incorporates elements of Cancer research and Pathology. Laura J. Esserman works mostly in the field of Surgery, limiting it down to concerns involving Mastectomy and, occasionally, Implant.
Laura J. Esserman mainly focuses on Breast cancer, Internal medicine, Oncology, Cancer and Neoadjuvant therapy. Laura J. Esserman is involved in the study of Breast cancer that focuses on Breast cancer screening in particular. Her research in Oncology intersects with topics in MammaPrint, Clinical endpoint, Proportional hazards model, Hazard ratio and Cohort.
The concepts of her Cancer study are interwoven with issues in Biomarker and Confidence interval. In her study, which falls under the umbrella issue of Neoadjuvant therapy, Recurrence free survival is strongly linked to Radiology. She interconnects Psychological intervention and Quality of life in the investigation of issues within Clinical trial.
Her primary areas of investigation include Breast cancer, Internal medicine, Oncology, Cancer and Neoadjuvant therapy. The various areas that Laura J. Esserman examines in her Breast cancer study include Biomarker, Area under the curve, Chemotherapy, Magnetic resonance imaging and Stage. Her studies deal with areas such as Letrozole, Tamoxifen, Estrogen receptor, Hazard ratio and Triple-negative breast cancer as well as Oncology.
She has researched Cancer in several fields, including Family medicine and Confidence interval. Her Neoadjuvant therapy research is multidisciplinary, incorporating elements of Clinical endpoint, Clinical trial, Randomized controlled trial, Hormone receptor and Proportional hazards model. Her biological study deals with issues like Protein expression, which deal with fields such as Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
Koei Chin;Sandy DeVries;Jane Fridlyand;Paul T. Spellman.
Cancer Cell (2006)
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis;Li Ding;Dong Shen;Jingqin Luo.
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial
Jayant S Vaidya;Jayant S Vaidya;Frederik Wenz;Max Bulsara;Jeffrey S Tobias.
The Lancet (2014)
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial
Jayant S Vaidya;David J Joseph;Jeffrey S Tobias;Max Bulsara.
The Lancet (2010)
Rethinking Screening for Breast Cancer and Prostate Cancer
Laura Esserman;Yiwey Shieh;Ian Thompson.
I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
AD Barker;CC Sigman;GJ Kelloff;NM Hylton.
Clinical Pharmacology & Therapeutics (2009)
Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update
James L. Khatcheressian;Patricia Hurley;Elissa Bantug;Laura J. Esserman.
Journal of Clinical Oncology (2013)
Overdiagnosis and Overtreatment in Cancer: An Opportunity for Improvement
Laura J. Esserman;Ian M. Thompson;Brian Reid.
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
Matthew J. Ellis;Vera J. Suman;Jeremy Hoog;Li Lin.
Journal of Clinical Oncology (2011)
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Christos Hatzis;Lajos Pusztai;Vicente Valero;Daniel J. Booser.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: